GlassScriptPhysician profile
Brandy Pelphrey
NPI 1104300946
$1,239.35
in general payments reported to CMS, 2019-2025
18 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $237 · 2023: $219 · 2024: $198 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $218.68 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $214.80 | 2022-2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $166.92 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $154.03 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $82.27 | 2021-2024 | |
| Exact Sciences Corporation | $59.45 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $54.48 | 2022-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Abbvie INC. | $42.06 | 2021 | |
| Sumitomo Pharma America, INC. | $34.10 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.13 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.53 | 2023-2024 | Xifaxan |
| Dexcom, INC. | $21.20 | 2022 | |
| Abiomed | $19.17 | 2025 | |
| Abbott Laboratories | $18.25 | 2024 | Freestyle Libre 3 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.15 | 2024 | Veozah |
| Pfizer INC. | $14.94 | 2024 | |
| Endogastric Solutions, INC | $10.24 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Pelphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.